A simple method for the preparation of c&-dichloro(1,4,7-triazacyclononane)platinum(ll), c&-Pt(tacn)Cl2 is presented, together with the results of screening the compound against the K-562 (leukemia) and SK-OV-3 (ovarian) human cancer cell lines. While the compound shows no activity against K-562 cells, there is evidence for some cytotoxicity against SK-OV-3. The compound is much less effective than cisplatin, and its limited solubility restricts the useable concentration range.
INTRODUCTION
While the matriarchal platinum anti-cancer agent, cisplatin, has been known for 150 years, its efficacy in the treatment of a variety of types of cancer was only discovered serendipitously by Rosenberg in the 1960's /1-3/. Since its approval for clinical use in 1978, it has developed into a $500 M a year industry, and has proved very successful in the treatment of testicular and ovarian cancer, as well as contributing to the treatment of lymphomas, head and neck, and bladder cancer/4/. However, the clinical use of cisplatin has several drawbacks. These include severe nausea and vomiting and severe nephrotoxicity/5/. While these problems have been ameliorated by aggressive diuresis and the use of anti-emetics, a "second-generation" of platinum anti-cancer agents were sought/6/. In these platins, chloro-ligands were replaced by more stable chelating ligands, resulting in complexes that were found to have lower renal toxicity, while retaining antitumour activity /7/. A key example is carboplatin, which causes significantly less nausea, vomiting and nephrotoxicity than cisplatin, but is as effective in the treatment of ovarian cancer/8/.
'ol. 9, A:os. !-, 20 Our laboratory has been interested in the structure and redox activity of transition metal macrocycles/13/. We have recently, turned our attention to the investigation of platinum complexes of meso-and racmacrocycles bearing pendant carboxylato-arms, to determine whether these macrocycles stabilize platinum(IV) complexes, that will be substitutionally inert, and that may be reduced by cysteine to the platinum(II) form/14/. In that study we found that the great thermodynamic stability of the platinum(IV) complexes, imparted by the "macrocyclic effect"/15/and by the negatively-charged pendant arms induced disproportionation of the platinum(If) compounds (formed by reduction of the Pt(IV) forms by cysteine), resulting in the precipitation of platinum(0) metal, free maerocycle and reformation of the platiunum(IV) complex. Thus these compounds were deemed not to be viable candidates as anti-tumour drugs. Consequently, we are presently examining the anti-cancer potential of platinum macrocycles where the propensity for disproportionation is avoided.Hence the present work examines the anti-cancer potential of the title compound, cis-dichloro-(1,4,7-triazacyclononane)platinum(II), cis-Pt(tacn)CI2.
cis-Pt(tacn)CI2.
The tacn macrocycle is too small to encapsulate a central metal ion, thus no disproportionation is expected, since the platinum ion is coordinated in an exocyclic fashion. We report here a facile synthesis of the title compound, together with the results of its screening against two human cancer cell lines, K-562 (leukemia) and SK-OV-3 (ovarian). Robert 
Solubility of cis-Pt(tacn)Cl2
An excess of solid cis-Pt(tacn)Cl2 was shaken with 9% w/v saline solution and thermostated at 25C in a recirculating water bath. The saturated solution was filtered and analysed for platinum concentration by Atomic Absorption spectrometry. The saturated solution was found to contain 704 ppm of platinum, equating to a molar solubility of 3.6 x 10 "3 tool drrl"3.
In vitro screening
The cell lines tested were K-562 (leukemia) and SK-OV-3 (ovarian The low solubility of the compound prevented the measurement of a 3C NMR spectrum in solution.
However, a solid state C spectrum was run (at Dalhousie U.). A single broad peak, centred at 54.77 ppm was obtained. The broadness of the peak may be explained by the nature of the solid sample being amorphous.
vitro screening respectively. This may be compared to cisplatin, where corresponding survival percentages were 75, 14 and zero respectively. Thus we may conclude that while cis-Pt(tacn)Cl2 shows some efficacy for apoptosis in ovarian cells, it is much less effective than cisplatin. This is somewhat surprising, since the complex contains the well-recognised important "cis-dichloroplatinum(ll)" moiety, analogous to cisplatin. Further, its limited Table 2 Average % cell survival for cytotoxicity assays for SK-OV-3 cells treated with cis-Pt(tacn)Cl2, for a series of concentrations of the compound, for 24, 48 and 72 hours.
[cis-Pt(tacn)C12] (mol dm"3) blank 6.0x 10 Facile ,Fnthesis of cis-Dichloro-(7, 4, 7-Triazao,clononane) PlatinumaO and it Screen.#g solubility in saline solution further inhibits its us,. Current work in our laboratory is directed towards increasing the lypophilicity of platinum-taen complexes by appending aliphatic tails to the macrocycle. This should serve to increase the bioavailability of the compound. Use of cyclodcxtrins as drug-carriers will address the solubility problems. This work is ongoing, and will be reported later.
